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Abstract
The polycystic ovary syndrome (PCOS) is the most frequent endocrinopathy in women in reproductive age with the so far
undetermined causes of development. In the etiopathogenesis of PCOS, the role of insulin resistance is emphasised, which was an
indication for the attempts at using chromium III salts (Cr) in augmenting pharmacotherapy applied in patients. The analysis of
the usefulness and efficacy of this approach was the direct goal of this thesis. Animal tests confirmed the efficacy of chromium in
maintaining the appropriate level of glycaemia and insulinaemia, normalisation of plasma concentrations of microelements and
also a correlation between the Cr level, insulin and dehydroepiandrosterone (DHEA) was found. A decrease in the expression of
3β-hydroxysteroid dehydrogenase and 17β-hydroxysteroid dehydrogenase was identified in adipose tissue. Clinical studies,
although sparse, show that the supplementation with chromium can improve BMI and the parameters evaluating the control of
glycaemia and increase the chances for ovulation and regular menstruation. However, the small number and a variability in study
protocols makes comparing them very difficult. A completely new subject that has not been yet studied is the possibility of using
chromium in levelling mood disorders in patients with PCOS. Currently, there are still no sufficient proofs for introducing
chromium as a standard in treating and preventing insulin resistance in patients with PCOS. However, this direction remains
open, and treating insulin resistance is an important challenge in clinical practice.
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Introduction
Polycystic ovary syndrome (PCOS) is one of the most frequent
endocrinopathies in women in reproductive age and in adoles-
cence. In accordance with American data, this disorder is diag-
nosed in 4–12% of women; however, according to European
data, this condition may occur twice as frequent [1–3]. The
frequency of diagnosing in a given country is influenced by
the prevalence of obesity and also ethnic and racial differences,
as described in the epidemiological literature and in the clinical
image of this disorder [4]. The causes of PCOS are still being
studied; there is an ongoing search for the genes responsible for
the manifestation of the disease, and the clinical image is
extraordinarily heterogeneous [2, 5]. There are gynaecological
and metabolic symptoms; all of them influence patient’s
psychological condition and self-esteem [6, 7].
One of the most important elements of the image of the
observed metabolic disorders is insulin resistance and a whole
set of glycaemic disorders. In patients with PCOS, obesity and
dyslipidaemia are more frequent [8, 9]. This led to the hypoth-
esis that the application of supplementation with chromium
(III) indicated as an microelement facilitating in maintaining
normal glycaemia and normal level of lipoprotein in plasma
and dealing with obesity [10].
Review Method
A review of Internet databases (PubMed, Ebsco and
ScienceDirect) and medical journals was performed,
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searching for papers in Polish and in English from years
2000–2018. The following keywords and their combinations
were used: polycystic ovary syndrome (PCOS, zespół
policystycznych jajników), chromium (chrom), chromium
picolinate (pikolinian chromu), chromium chloride (chlorek
chromu), glucose intolerance (nietolerancja glukozy), lean
body mass (beztłuszczowa masa ciała), lipid profile (profil
lipidowy), mood disorders (zaburzenia nastroju) and depres-
sion (depresja). The analysis included original, case studies
and review papers related to the studied subject.
Results
Polycystic Ovary Syndrome
PCOS was described for the first time by Stein and Leventhal
in 1935. The first name of the condition was based on both
their names. The current terminology is derived from the char-
acteristic image of an ovary with peripherally located cysts.
PCOS is characterised by hyperandrogenism and ovary func-
tion and changes in their structure [2, 11]. Other names of the
syndrome include functional ovary androgenism, chronic
hyperandrogenic lack of ovulation, ovary dysmetabolic syn-
drome, sclerotic ovary syndrome, polycystic ovaries or the
aforementioned historical name: Stein–Leventhal syndrome.
PCOS Symptoms and Course of the Disease
Currently, in order to diagnose PCOS, the Rotterdam criteria
were approved by the American Society for Reproductive
Medicine and the European Society of Human Reproduction
and Embryology, in accordance with which PCOS is indicated
by two of the three symptoms: menstruation disorders or
amennorrhea with ovulation disorder or lack thereof; clinical
and/or biochemical signs of hyperandrogenism; presence of
polycystic ovaries in ultrasound, after prior elimination of oth-
er conditions related to hyperandrogenism [12].
PCOS frequently presents with acne, hirsutism, hair loss,
irregular menstruation and infertility. It increases the risk of
endometriosis and breast cancer, and it is also related to the
following disorders: dyslipidaemia, hypertension, cardiovas-
cular diseases and diabetes, fitting the consequences of a met-
abolic syndrome [13]. Hyperandrogenismmanifests by andro-
genic alopecia, hirsutism, acne lesions, increased hair loss,
oily skin, seborrhoeic lesions and clitoromegaly. Hirsutism,
one of the most frequent symptoms, assessed according to
the Ferriman–Gallwey score, is the presence of gruff, thick
and pigment-saturated hair in women in places typical for
men, e.g. upper lip, chin, chest, nape of the neck, lumbar
region, abdomen, thighs and feet [14]. A frequently appearing
skin symptom in women with PCOS is also acanthosis
nigricans, usually located on elbows, nape of the neck, armpits
and under breasts [15, 16]. More than half of the women
suffering from PCOS experience overweight and obesity, usu-
ally of the androidal type [8]. Increased body weight has neg-
ative influence on carbohydrate economy, which causes insu-
lin resistance, leading also to hyperinsulinaemia. It is thought
that high concentration of circulating insulin contributes to the
increased production of androgen in an ovary and to ovulation
disorders. In a significant part of patients, an abnormal lipid
profile is observed. Patients with PCOS are at high risk of
developing cardiovascular disease being its distant conse-
quence [17, 18].
PCOS is a condition strongly affecting mental health and
social functioning. In women with PCOS, an increased num-
ber of anxiety and/or depression incidents is reported [6, 7]. In
great majority of cases, this is connected with the clinical
image of this disorder, deteriorating the quality of life [6,
19]. It has been concluded that the increased level of free
testosterone in the plasma, one of the main anomalies in
PCOS, is correlated with the increased risk of depression.
There are studies reporting even sevenfold increase in the
frequency of suicides among patients [20]. Patients often have
a problem with their identity and social functioning. They feel
the difference between their appearance and the image of the
woman created by media. They withdraw from social life.
Also, the infertility present in 72% of patients contributes to
the development of serious psychosocial problems [8, 19, 21].
Dietary Treatment and Supplementation in PCOS
In the aspect of direct correlation between obesity and the
frequency of PCOS, it seems that diet therapy should play
the major role in managing the condition [22]. Studies re-
vealed disorders in the metabolism of many nutrients, such
as vitamin D, numerous minerals and omega-6 fatty acid
[23]. Therefore, dietary strategies and supplementation have
become points of interest of persons studying the problems of
women with PCOS [24]. Among others, the effects of dietary
supplementation with the application of inositol and folic acid
have been indicated [25, 26], and also interesting effects have
been observed regarding 12-week probiotic supplementation
[27].
Minimising insulin resistance can play a significant role in
controlling PCOS [28]. The development and understanding of
the phenomenon of insulin resistance in the pathogenesis of this
syndrome were an indication to search for new methods,
including adjusting the diet of patients [29]. One of the methods
leading to this effect was supposed to be chromium (III).
Chromium
Chromium (Cr) can be present at different levels of oxidation;
however, only Cr (III) is responsible for beneficial effects
[10]. The first publication on the biochemical role of Cr in
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mammal organisms was published in 1959 [30], and since that
time, it has been placed on the list of the elements necessary
for optimal functioning of living organisms. This was the re-
sult of observations indicating that the amount of Cr in the
structures of hair, plasma and sweat has negative correlation
with age, which differentiates it from most contaminations
accumulated in organisms with the passing of time. In patients
subjected to long-term parenteral nutrition, symptoms of Cr
deficiency were observed, manifested mainly by glucose in-
tolerance. These changes were easily treated after supplemen-
tation [31, 32]. Indications for its supplementation used to be
very broad; however, currently, Cr is one of the elements
causing the greatest controversies. It is argued that it does
not belong to the necessary microelements, but it evokes a
potential benefit and/or adverse effects. Adequate intake
(AI) was set based on estimated mean intakes and amounts
35 μg/day and 25 μg/day for young men and women, respec-
tively. In Poland, there are no separate recommendations for
this biometal AI, and no detailed guidelines on doses of PCOS
supplementation have been set.
Chromium, Glycaemic Level and Insulin Sensitivity
The first studies of the influence of Cr on maintaining the
proper glucose tolerance in rats were conducted in the late
1950s [30]. These observations were confirmed also in clini-
cal setting, in patients subjected to long-term parenteral nutri-
tion [33]. Chromium has become a popular subject of studies
regarding glucose intolerance and insulin resistance.
Currently, the conclusions are that only supplements including
yeast enriched with this metal have influence on the decrease
of concentration of glucose or glycated haemoglobin in blood
[34]. However, in the paper of Yin et al. comparing the studies
from years 2000–2012, it was shown that supplementation
can cause decrease of fasting glycaemia, but it has no influ-
ence on the concentration of glycated haemoglobin [35]. It is
indicated that Cr takes part in insulin signalling and increases
sensitivity to insulin of insulin-sensitive cells [36–38], and
deficiency, rare as it is, increases the risk of metabolic diseases
and diabetes [38].
Chromium and Lipid Metabolism
Animal study results confirm the positive influence of Cr on
lipid profile change [39] and the influence of supplementation
with this microelement on full cholesterol concentrations,
LDL and HDL cholesterol and triglycerides [40]. However,
clinical studies provide ambiguous results. Despite positive
observations from the turn of the twentieth and twenty-first
centuries [41], the studies of Kleefstra et al. [42] did not
achieve positive results of a 6-month supplementation with
chromium picolinate (III) (500 and 1000 μg/day). Only a
slight dependence between the content of Cr (III) in the serum
and the improvement of lipid indicators in the blood was
shown. The lack of influence of supplementation is also con-
firmed by the later studies with the use of yeast enriched with
Cr [34] and chromium picolinate (CrP) [43].
Chromium and Body Mass Control
Chromium dietary supplements were very popular in the
1990s and later, as products facilitating weight loss and in-
creasing muscle mass. To this day, many of them are still
offered by pharmacies and drugstores, which, in the context
of the frequency of obesity in women with PCOS, is another
indication at the necessity of analysing the activity and effica-
cy of such supplementation. Unfortunately, so far there have
not been any scientific reports proving the efficacy of supple-
mentation with Cr in decreasing the content of adipose tissue
and increasing muscle mass, against the marketing claims of
the manufacturers of dietary supplements [10]. A paper
summarising the results of publications regarding the applica-
tion of supplementation with Cr in persons with overweight
and obesity indicates that there have been a relatively small
number of studies with proper protocols: high heterogeneity
of intervention types and sample sizes, which usually were
small or moderate (622 subjects evaluated in total) [44]. The
intervention time was 12–16 weeks, and the observation for
potential adverse effects: 8–24 weeks. The results show that
Cr supplements in all doses have some influence on losing
weight after 12–16 weeks of supplementation, but the effec-
tive dosage cannot be yet determined. No decisive proofs in
the form of significant changes of BMI, waist circumference
or percentage content of adipose tissue were found. This is
significant in the light of the studies conducted by Pazderska
et al., which indicate that waist circumference in patients with
PCOS is suggested as a predictor of glucose and lipid metab-
olism disorders [45]. In the review of 10 studies performed by
Pitter [46], a significant differential effect to the benefit of CrP
was indicated; however, the clinical significance of this effect
is still disputed. Also, the safety of supplementation with CrP
in persons with overweight and obesity is still being deter-
mined, although reports on adverse effects of supplementation
with Cr are more casuistic in nature [47].
Supplementation with Chromium in PCOS
Due to the concomitance of PCOS and insulin resistance, an
attempt was made to apply supplementation with Cr in this
disorder. Studies conducted in animals showed the efficacy of
the increased supply of Cr in maintaining the proper level of
insulin and glucose in fasting conditions, an improvement of
the microelement levels in plasma, which were disturbed due
to a disease [48], and they confirmed the dependence between
the concentration of Cr, insulin and dehydroepiandrosterone
(DHEA) [48, 49]. Thanks to the mouse model of PCOS, the
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influence of the syndrome on phenotypical characteristics was
demonstrated: the mice developed abdominal obesity,
hyperandrogenism, hyperinsulinaemia, follicular atresia and
light hepatic steatosis. The model mice with Cr supplementa-
tion showed a tendency to decrease body weight gain, liver
mass and its steatosis was significantly lower in these animals;
however, Cr did not improve the morphology of ovaries. In
the adipose tissue of the supplemented animals, a decrease of
3β-hydroxysteroid and 17β-hydroxysteroid dehydrogenases
was revealed. In model animals, a reverse correlation between
the concentration of Cr in serum and in muscles and the con-
centration of insulin was noted, which points to the fact that
PCOS can cause a low level of Cr in serum and in muscles,
and it seems to lead to hyperinsulinaemia [47]. The analysis of
plasma concentrations of selected metals, including Cr, was
the subject of several papers and was reviewed in detail in
2016 [50]. Two studies evaluating plasma chromium levels
selected by Spritzer et al. did not indicate differences between
women with PCOS and controls.
As of now, several randomised placebo-controlled clinical
studies have been conducted in patients with PCOS. Amr and
Abdel-Rahim evaluated the influence of supplementation in
adolescents (age range, 14–17 years old) [51]. Thirty-five ad-
olescent girls with histories of menstruation disorders were
qualified for the study. In 6 months, subjects were given
1000 μg of CrP. After this period, the lack of significant
change of BMI was indicated; however, the number of sub-
jects with oligomenorrhoea/amenorrhoea decreased in the
supplemented group, and also a significant decrease of the
mean ovary volume and the total number of ovarian cysts
was observed. What is important, in the supplemented group,
the level of free testosterone in the serum was significantly
lower. However, no significant improvement was noted in the
image of acne and hirsutism.
The rest of the studies of the application of therapy or
supporting therapy of PCOS with Cr were conducted in ma-
ture women, and the meta-analysis of the results is presented
in review studies [52–55]. In Heshmati’s work [53], the final
meta-analysis included only five properly randomised and
placebo (or an approved drug)-controlled studies, with 137
women with PCOS in total. The authors indicated three stud-
ies assessing Cr as a single supplement [56–58]. Two of them
assessed Cr in comparison to metformin [59, 60]. Populations
of the studied groups were from 6 to 46 women, and the
applied diagnostics of PCOS complied with the criteria of
the Rotterdam consensus [12]. These studies were conducted
in the USA, Egypt and Iran. All the women were in reproduc-
tive age, and the intervention time was from 6 weeks to
6 months. Chromium, in comparison to placebo or other ther-
apies, caused significant changes in the insulin resistance
markers (summary data analysis from five studies indicated
significantly lower HOMA-IR values in the group supple-
mented with chromium). The study describing the influence
of supplementation on HOMA-B showed a significant differ-
ence. In this study, after 8 weeks of supplementation in wom-
en with PCOS, also a significant decrease in HOMA-IR and
an increase of the QUICKI result were reported, in compari-
son to placebo [57]. Comparing Cr with metformin treatment,
it was indicated that supplementation of diet with Cr was not
related to insulin concentration [59, 60]. Meta-analysis con-
ducted by Tang et al. [55] indicates the improvement in insulin
sensitivity; however, it has failed to show a beneficial effect of
Cr supplementation on the level of total and free testosterone.
Data analysis showed no effect of supplementation on body
mass, fasting insulin and glucose or serum lipid levels. Also,
there were no significant differences in luteinizing hormone
(LH), follicle-stimulating hormone (FSH) and prolactin
(PRL). Maleki concludes that a longer period of supplemen-
tation is required to obtain a significant effect of Cr intake on
the level of sex hormones in the plasma [54]. The conducted
studies and their meta-analyses do not provide an unequivocal
answer regarding the efficacy of supplementation, and the
observed effects are too poor to allow for the implementation
of such an approach to the standard therapy of patients with
PCOS.
Chromium and Treatment of Mood Disorders in PCOS
According to Kurek and Babiarczyk, due to the multidimen-
sional character of the problems related to PCOS in women,
they should be provided complex care including the physical
and psychosocial problems [6]. Treatment of physical disor-
ders should be conducted in accordance with the current
needs, which is aimed at reaching the goals they have chosen.
The psychosocial disorders, which are very often skipped in
the process of treatment, should be paid special attention, and
these women should be provided psychological help in fight-
ing depression, which often appears in this condition [6, 7].
The first information indicating the possibility of antidepres-
sant activity of Cr is from the 1990s. It was described that the
symptoms of atypical depression, dysthymia, seasonal affec-
tive disorders and daily mood swings decreased. Due to the
fact that in some women with PCOS depressive states related
to unsuccessful attempts at getting pregnant, high BMI and
low self-esteem, preparations with Cr can have positive influ-
ence; however, this has not been studied so far.
The mechanism of antidepressant activity of Cr seems to be
of pharmacological nature [61–63], as deficiency of this metal
is rare [64, 65], and the effective doses are relatively high both
in animal tests [61–63] and in clinical application: Cr salt,
administered in dose 400–600 μg/day, was effective in patient
with depression [66–68].
The antidepressant activity of Cr studied in animal models
of depression depends (to various degrees) on noradrenergic,
dopaminergic and serotonin signalling. It was shown that the
antidepressant activity of chromium chloride (CrCl3) is
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partially dependent on serotonin receptors 5-HT1A and 5-
HT2A [63]. On the other hand, the noradrenergic mechanism
was indicated in the studies with the application of adrenergic
receptor antagonists (propranolol, prazosin, yohimbine) and
the reinforcement of the antidepressant activity of reboxetine
(selective inhibitor of noradrenaline uptake) [63]. Also, the
role of dopaminergic system was indicated [63]. The involve-
ment of the monoamine systems was also indicated by
Franklin and Odontiadis [69], who demonstrated increase in
the level of serotonin and its metabolites, as well as a change
in the number of 5HT2A receptors of the downregulation type.
Glutamatergic system takes part in the antidepressant activity
of Cr through receptors AMPA (α-amino-3-hydroxy-5-meth-
yl-4-isoxazolepropionic acid receptor) and NMDA (N-meth-
yl-D-aspartate receptor) [62]. Additionally, Khanam and Pillai
[70] suggested the involvement of K+ channels; however, this
has never been confirmed. The complex mechanism in corre-
lation with an interesting clinical profile (activity in dysthy-
mic, seasonal disorders and atypical depression) and the influ-
ence on carbohydrate metabolism, and perhaps also lipid me-
tabolism, makes Cr supplementation in patient with PCOS a
still interesting study subject.
Summary
Chromium gained its greatest popularity by the end of the
twentieth century. In scientific literature, one can find an enor-
mous number of studies concerning the influence of supple-
mentation on carbohydrate–lipid economy of the body, but not
only on that aspect. The indications regarding the influence on
the markers describing insulin resistance allowed to presume
the efficacy of such supplementation in PCOS.
The indicated mechanisms of action for Cr confirmed in
animal tests are unfortunately not always confirmed in the
conducted clinical studies. The efficacy of supplementation
in diabetes and dyslipidaemias is undermined, in maintaining
appropriate body weight—negated. The available reports on
the role of Cr are often contradictory, and the state of knowl-
edge does not confirm the previous assumptions fully, which,
unfortunately, often is the result of poor planning of research
works and especially using very small patient groups.
The role of Cr supplementation in PCOS remains unsolved.
An interesting phenomenon is especially the possibility of this
element influencing the mood, which constitutes a big chal-
lenge in the discussed condition. A significant factor for using
Cr supplementation in patients with PCOS can be also the fact
that in animal tests, low Cr level was observed in serum and in
muscles with concomitant hyperinsulinaemia. Nevertheless,
in order to unequivocally assess the efficacy of Cr supplemen-
tation in the discussed condition, it is necessary to conduct
further studies in this direction of sufficient sample size for
sufficient duration in well-defined populations.
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